The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria

American Journal of Surgical Pathology

Volumn 28, Issue 11, 2004, Pages 1532-1536

  Ribalta, Teresa ^b   McCutcheon, Ian E ^a   Aldape, Kenneth D ^a   Bruner, Janet M ^a   Fuller, Gregory N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Immunohistochemistry; Meningioma; Mitotic figure; Phosphohistone H3 (PHH3); Tumor grade

Indexed keywords

PHOSPHOHISTONE H3 ANTIBODY; PROTEIN ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY LABELING; ANTIBODY SPECIFICITY; APOPTOSIS; CANCER CLASSIFICATION; CANCER GRADING; CELL PROLIFERATION; CONSENSUS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MITOSIS INDEX; MITOSIS RATE; OBSERVER VARIATION; QUANTITATIVE ANALYSIS; RELIABILITY; REVIEW; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TECHNIQUE; TISSUE SECTION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; CELL PROLIFERATION; CHILD; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MITOTIC INDEX; PHOSPHORYLATION;

EID: 7044223238     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000141389.06925.d5     Document Type: Review

References (25)

1. Abramovich CM, Prayson RA. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol. 1998;29:1420-1427.
2. KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol. 2001;32: 970-975.
3. Baehner R, Weidner N. Enhanced mitotic figure counting in breast carcinomas using a mitosis-specific antibody: anti-phosphohistone-H3 (PHH3). Mod Pathol. 2000;13:17A.
4. Gurley LR, D'Anna JA, Barhan SS, et al. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem. 1978;84:1-15.
5. Hendzel MJ, Wei Y, Mancini MA, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;106:348-360.
6. Hendzel MJ, Nishioka WK, Raymond Y, et al. Chromatin condensation is not associated with apoptosis. J Biol Chem. 1998;273:24470-24478.
7. Hsu DW, Efird JT, Hedley-Whyte ET. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF-α) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurol. 1998; 24:441-452.
8. Jääskeläinen J. Seemingly complete removal of histologically benign intracranial meningioma: later recurrence rate and factors predicting recurrence in 657 patients: a multivariate analysis. Surg Neurol. 1986;26:461-469.
9. Juan G, Traganos F, James WM, et al. Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry. 1998;32:71-77.
10. Kleihues P, Cavenee WK. eds. Meningiomas. In: Pathology and Genetics of Tumours of the Nervous System: World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2000:176-184.
11. Langford LA, Cooksley CS, DeMonte F. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Hum Pathol. 1996;27:350-354.
12. Matsuno A, Fujimaki T, Sasaki T, et al. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol. 1996;91:504-510.
13. McDermott MW, Quinones-Hinosa A, Fuller GN, et al. Meningiomas, In: Levin VA, ed. Cancer in the Nervous System. New York: Oxford University; 2002:269-299.
14. Møller M-L, Broendstrup O. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry. J Neurooncol. 1997;34: 241-246.
15. Nakaguchi H, Fujimaki T, Matsuno A, et al. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry. Cancer. 1999;85:2249-2254.
16. Nakasu S, Li DH, Okabe H, et al. Significance of MIB-1 staining indices in meningiomas. Am J Surg Pathol. 2001;25:472-478.
17. Ohta M, Iwaki T, Kitamoto T, et al. MIB-1 staining index and scoring of histologic features in meningioma. Cancer. 1994;74:3176-3188.
18. Perry A, Stafford SL, Scheithauer BW, et al. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997;21:1455-1465.
19. Perry A, Stafford SL, Scheithauer BW, et al. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer. 1998;82:2262-2269.
20. Perry A, Stafford SL, Scheithauer BW, et al. Malignancy in meningiomas: a clinicopathologic study of 116 patients with grading implications. Cancer. 1999;85:2046-2056.
21. Prayson RA. Malignant meningioma: a clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry. Am J Clin Pathol. 1996;105:719-726.
22. Prayson RA. Cell proliferation and tumors of the central nervous system: 1. Evaluation of mitotic activity. J Neuropathol Exp Neurol. 2002;61: 501-509.
23. Salmon I, Kiss R, Levivier M, et al. Characterization of nuclear DNA content, proliferation index, and nuclear size in a series of 181 meningiomas, including benign primary, recurrent, and malignant tumors. Am J Surg Pathol. 1993;17:239-247.
24. Tse JYM, Ng H-K, Lo K-W, et al. Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas. Hum Pathol. 1998;29:1200-1207.
25. Younis GA, Sawaya R, De Monte F, et al. Aggressive meningeal tumors: review of a series. J Neurosurg. 1995;82:17-27.